Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 29 Jul 2024
New case suggests HIV cure can be achieved independent of stem cell transplant donor CCR5 status
Read Full NewsPsychotropics are associated with increased BMI, and users with a high BMI genetic risk score and an unhealthy lifestyle have triple the risk for CVD, new research shows.
Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.
In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.
A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.
In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.
A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to standard treatment in advanced squamous NSCLC.
In an interim analysis of a randomized phase 2 trial, asandeutertinib improved intracranial response and intracranial PFS vs osimertinib in patients with EGFR-mutated NSCLC with brain metastases.
1.
Study sets benchmark for treatment of advanced cervical cancer
2.
Tumor characteristics found to differ for melanomas in children, teens and young adults
3.
Making informed decisions and managing regret after prostate cancer treatment
4.
Oral drug combination extends progression-free survival in advanced ER-positive breast cancer
5.
Physician Fights Insurer to Cover Her Baby's Brain Cancer Treatment
1.
Circulating Tumor Cells & Platelet Interactions: Crosstalk for Therapeutic Advances
2.
Future-Ready Cancer Screening: What Every Clinician Should Know in 2025
3.
Esophageal Cancer Survival Rates and Outcomes: Evidence-Based Insights from Oncology Studies
4.
Exploring the Hope of New Treatments for Rhabdomyosarcoma
5.
Understanding Epidural Hematoma: Symptoms, Causes and Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
2.
Navigating the Complexities of Ph Negative ALL - Part XIV
3.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
4.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
5.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge